As competition in the weight loss drug market progressively intensifies, the latest Phase III clinical data disclosed by BrightGene Bio-Medical (688166.SH) for BGM0504 has reignited market attention.
Why Quantum-Resistant Encryption is Non-Negotiable appeared first on Read the Gopher Security's Quantum Safety Blog. The "ten ...
K92 Mining Inc. (“K92 ” or the “Company ”) (TSX: KNT; OTCQX: KNTNF) is pleased to announce financial results for the three ...
Broyhill Equity Composite declined 6.0% in Q1 2026, lagging global benchmarks. Read the full analysis for insights on ...
We appreciate you taking the time out of your busy schedules to attend our Investors Meeting for FY 2025 financial results, management priorities and business strategies. Today's session will begin ...
The Ministry is designing a new National Renewable Energy Database platform to enable the allocation preparation ...
Seasonal depression doesn’t announce itself dramatically. It usually arrives gradually – you start sleeping longer, stop ...
TAGMO Clinical Readouts -- Initial results for head and neck, and upper GI adenocarcinoma cohorts are expected midyear, with ...
Kim Yongbeom, policy chief at the Blue House, has proposed the concept of a so-called “national dividend,” which would return ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results